NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Hemispherx Biopharma, Inc. (NYSE: HEB), a specialty pharmaceutical company, engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.
On April 30th, HEB announced significant progress in its Ampligen recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) under the leadership of the principal investigator, Robert Edwards, MD.
Get more info about the ovarian cancer program as a potential catalyst here READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/hemispherx/
On April 2nd HEB announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, N.Y. evaluating Hemispherx' experimental drug Ampligen® (rintatolimod), a dsRNA TLR3 agonist, in combination with Merck's Keytruda® (pembrolizumab), an anti-PD-1 check-point blockade therapy, in the treatment of metastatic triple-negative breast cancer. The study's first participant received initial dosing this week. The phase I trial seeks to enroll at least six patients.
What is HEB doing in the interest of transparency about its Ampligen product READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/hemispherx/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CONTACT: [email protected]
SOURCE: Traders News Source